Forest Lexapro maintenance claim
Executive Summary
Forest Lexapro receives supplemental approval for prevention of relapse following long-term treatment of major depressive disorder Aug. 29. Escitalopram longer-term efficacy data will replace data from the predecessor antidepressant Celexa (citalopram) in Lexapro's Aug. 14 approved labeling (1"The Pink Sheet" Aug. 19, p. 3). The sNDA was filed Oct. 29, seven months after the NDA was filed...
You may also be interested in...
Forest Lexapro Approval Includes Label Claim Of Greater Potency Than Celexa
Forest's Lexapro (escitalopram) label includes a statement of greater potency than its predecessor antidepressant Celexa (citalopram)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.